Amreet K. Aujla, MD
Hospitalist · Fresno
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 9 years
- Graduated 2017
Offices
1 location · Community Foundation Medical Group · 282 clinicians in this group
Hospitals listed: Clovis Community Medical Center · Saint Agnes Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Aujla’s office at (559) 440-0450 to ask if they take your plan before you enroll.
California Medical Board record
Licence A164424 · Current
Licensed to practise in California · since 2019 · expires 2027-08-31 · Baba Farid University of Health Sciences Dayanand Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Internal Medicine
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Clovis Community Medical CenterClovis, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Community Medical Centers, which runs 4 hospitalsPatients rate it 3 of 5 · 80% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.7 (12.1 to 17.7) · 421 cases, Jan 2024 – Dec 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.692, Oct 2024 – Sep 2025
- Saint Agnes Medical CenterFresno, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of Trinity Health, which runs 105 hospitals in 16 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.312, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.141, Oct 2024 – Sep 2025
See every measure and the patient survey for Clovis Community Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 0 better, 6 the same, 1 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.7 (12.1 to 17.7) · 421 cases | Worse | Jan 2024 – Dec 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.692 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.97 (0.04 to 1.89) · 1,840 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.16 (0.86 to 1.45) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 217.06 (167.45 to 266.67) · 84 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 69 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.1 · 165 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.4 · 161 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 14 · 507 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 798 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 336 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 3,771 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.39) · 8,649 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.08 to 0.46) · 9,146 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.46 (1.47 to 5.45) · 1,654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.19 (0.61 to 3.78) · 387 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.18 (0.7 to 3.66) · 1,578 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 13.47 (7.08 to 19.87) · 374 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.99 (1.37 to 8.61) · 379 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.58 (0.13 to 3.04) · 405 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.8 (0.23 to 1.38) · 8,198 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 90 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.651 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.922 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.449 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.509 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.3 · 210 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 23 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -1.5 · 152 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 58.4 · 556 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18 · 769 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.8 · 802 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (4 to 7.4) · 421 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.2 · 91 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 93 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 200 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.8 to 15.6) · 2,398 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 720 cases | No different | Jan 2024 – Dec 2024 |
What patients said (441 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 80% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Saint Agnes Medical Center
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 6 the same, 0 worse of 8 measures. Readmissions: 0 better, 6 the same, 3 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.312 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.141 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.18 to 1.94) · 2,342 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 197.82 (152.64 to 243.01) · 103 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.3 · 300 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.9 · 295 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.8 · 768 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.8 · 969 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 304 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 4,305 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.06 to 0.42) · 11,641 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.07 to 0.43) · 12,213 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.76 (2.91 to 6.61) · 2,466 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.09 (0 to 2.49) · 864 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.61 (0.26 to 2.96) · 2,362 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.1 (5.39 to 14.81) · 900 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.4 (1.2 to 7.59) · 882 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.84 (0.41 to 3.27) · 541 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.67 (0.14 to 1.19) · 9,626 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 58 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.835 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 1.182 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.004 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 412 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.6 · 1,002 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 28.8 · 296 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 25.5 · 894 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 17.8 · 981 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 1,061 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 13.4 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 412 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.3 (9.6 to 15.9) · 1,324 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 863 cases | No different | Jan 2024 – Dec 2024 |
What patients said (812 patients answered, 32% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$93,268
Medicare paid this office $93,268 for 389 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| New patient visit (45+ min) | 184 | $20,621 | $112 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 72 | $14,850 | $206 |
| Return visit (30+ min) | 85 | $12,497 | $101 |
| Biopsy of large bowel using a flexible endoscope | 116 | $9,992 | $85 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 117 | $9,868 | $82 |
See all 12 services
| New patient visit (45+ min) | 184 | $20,621 | $112 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 72 | $14,850 | $206 |
| Return visit (30+ min) | 85 | $12,497 | $101 |
| Biopsy of large bowel using a flexible endoscope | 116 | $9,992 | $85 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 117 | $9,868 | $82 |
| Short return visit (20+ min) | 42 | $3,551 | $71 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 28 | $2,843 | $102 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 30 | $2,819 | $94 |
| Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | 24 | $2,375 | $95 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 130 | $1,946 | $13 |
| New patient visit (30+ min) | 20 | $1,541 | $77 |
| Biopsy of large bowel using a flexible endoscope | 12 | $1,526 | $127 |
Procedures Medicare counted
| Colonoscopy | 21 | More than 48% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 72 | More than 70% of doctors who do this |
Procedures year by year
| Procedure | 2023 | 2024 |
|---|---|---|
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 15 | 121 |
| Biopsy of large bowel using a flexible endoscope | – | 129 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | – | 72 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | – | 30 |
| Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | – | 25 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
389 Original Medicare patients in 2024. Average age 73 · Under 65 13% · 85 and older 17% · Women 62% · Also on Medicaid 41% · Health risk score 1.78. At or below the middle of the specialty; the typical hospitalist clinician is at 2.49.
Conditions among them: High blood pressure 75% · Diabetes 44% · Chronic kidney disease 37% · Coronary heart disease 36% · Heart failure 31% · Depression 25% · Atrial fibrillation 21% · Cancer 16% · COPD 16% · Dementia 9% · Stroke 7%.
The office billed $839,994, Medicare allowed $120,407 and paid $93,268; for 1,015 services of 34 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 389 | 1,015 | 73 | 1.78 | $839,994 | $93,268 |
| 2023 | 52 | 93 | 71 | 1.33 | $86,230 | $10,675 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| New patient visit (45+ min) | 36 | $4,844 | $135 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 15 | $1,153 | $77 |
Medicaid work
$6,605 in 2024
Medicaid paid $6,605 for 448 billed services this clinician did in 2024, up to 36 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| COLONOSCOPY AND BIOPSY | 94 | $2,098 |
| New patient visit (45+ min) | 131 | $2,030 |
| Upper gastrointestinal endoscopy with biopsy | 130 | $1,240 |
| Service | 13 | $889 |
| Service | 13 | $159 |
| Return visit (30+ min) | 40 | $140 |
| Injection, propofol, 10 mg | 13 | $50 |
| Service | 14 | $0 |
| 2024 | 448 | 8 | 36 | $6,605 |
| 2023 | 49 | 1 | 28 | $0 |
See the largest Medicaid services in earlier years
2023
| New patient visit (45+ min) | 49 | $0 |
Drugs they prescribed that Part D paid
$310,506
Pharmacies billed $310,506 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 520) in 2024. At or below the middle of the specialty; the typical hospitalist clinician is at 4%.
376 generic and 144 brand-name prescriptions · $310,506 in drug cost · 21 antibiotic prescriptions to 11 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Linzess | 55 | $58,524 | $1,064 |
| Gavilyte-G | 160 | $2,386 | $15 |
| Pantoprazole | 107 | $1,756 | $16 |
| Peg-3350 and Electrolytes | 70 | $1,018 | $15 |
| Omeprazole | 22 | $335 | $15 |
See all 7 drugs
| Linzess | 55 | $58,524 | $1,064 |
| Gavilyte-G | 160 | $2,386 | $15 |
| Pantoprazole | 107 | $1,756 | $16 |
| Peg-3350 and Electrolytes | 70 | $1,018 | $15 |
| Omeprazole | 22 | $335 | $15 |
| Gavilyte-C | 12 | $206 | $17 |
| Metronidazole | 11 | $98 | $9 |
Year by year
| 2024 | 520 | 303 | 0% (0) | 28% | $310,506 |
| 2023 | 63 | 51 | 0% (0) | 22% | $3,206 |
| 2022 | 38 | 21 | None | None | $2,271 |
| 2021 | 42 | 23 | 0% (0) | None | $6,107 |
| 2020 | 223 | 37 | 0% (0) | None | $33,140 |
| 2019 | 463 | 59 | None | None | $42,054 |
| 2018 | 495 | 59 | None | None | $30,677 |
| 2017 | 114 | 20 | 0% (0) | None | $9,471 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Gavilyte-G | 17 | $260 | $15 |
| Pantoprazole | 13 | $175 | $13 |
2020: 6 drugs
| Januvia | 26 | $16,763 | $645 |
| Tamsulosin | 11 | $290 | $26 |
| Pantoprazole | 11 | $227 | $21 |
| Atorvastatin | 11 | $114 | $10 |
| Amlodipine Besylate | 19 | $105 | $6 |
| Lisinopril | 11 | $75 | $7 |
2019: 11 drugs
| Januvia | 29 | $18,377 | $634 |
| Atorvastatin | 38 | $505 | $13 |
| Pantoprazole | 24 | $318 | $13 |
| Gabapentin | 11 | $263 | $24 |
| Lisinopril | 31 | $194 | $6 |
| Tamsulosin | 12 | $171 | $14 |
| Metformin | 27 | $169 | $6 |
| Amlodipine Besylate | 24 | $98 | $4 |
| Hydrochlorothiazide | 15 | $95 | $6 |
| Methocarbamol | 11 | $76 | $7 |
| Metoprolol | 11 | $45 | $4 |
2018: 11 drugs
| Januvia | 22 | $10,461 | $475 |
| Esomeprazole Magnesium | 13 | $1,186 | $91 |
| Gabapentin | 18 | $518 | $29 |
| Atorvastatin | 36 | $305 | $8 |
| Pantoprazole | 20 | $231 | $12 |
| Lisinopril | 48 | $191 | $4 |
| Hydrochlorothiazide | 28 | $166 | $6 |
| Metformin | 30 | $118 | $4 |
| Amlodipine Besylate | 19 | $116 | $6 |
| Montelukast | 12 | $96 | $8 |
| Famotidine | 16 | $89 | $6 |
Money from drug and device companies
$1,111 in 2025
| 2025 | 12 | 64 | None | $1,111 |
| 2024 | 10 | 35 | None | $693 |
| 2023 | 12 | 38 | None | $1,158 |
| 2022 | 11 | 61 | None | $1,606 |
| 2021 | 6 | 37 | None | $1,175 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Rinvoq | $449 | 23 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $232 | 18 payments
|
| Madrigal Pharmaceuticals | Rezdiffra | $149 | 7 payments
|
| Ardelyx | Ibsrela | $73 | 4 payments
|
| Phathom Pharmaceuticals | Voquezna | $54 | 5 payments
|
| Orphalan | Cuvrior | $30 | 1 payment
|
See all 64 published payments
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-12-15 | Xifaxan | $21 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-12-15 | Xifaxan | $11 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-12-15 | Xifaxan | $8 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-12-15 | Xifaxan | $4 |
| Abbvie | Meals · 2025-12-11 | Rinvoq | $16 |
| Abbvie | Meals · 2025-12-09 | Rinvoq | $25 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-12-01 | Xifaxan | $17 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-11-24 | Xifaxan | $7 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-11-24 | Xifaxan | $5 |
| Novo Nordisk | Meals · 2025-11-19 | Wegovy | $23 |
| Phathom Pharmaceuticals | Meals · 2025-11-18 | Voquezna | $15 |
| Phathom Pharmaceuticals | Meals · 2025-11-14 | Voquezna | $8 |
| Abbvie | Meals · 2025-11-12 | Rinvoq | $23 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-11-10 | Xifaxan | $6 |
| Abbvie | Meals · 2025-11-04 | Rinvoq | $20 |
| Phathom Pharmaceuticals | Meals · 2025-10-28 | Voquezna | $10 |
| Orphalan | Meals · 2025-10-23 | Cuvrior | $30 |
| Madrigal Pharmaceuticals | Meals · 2025-10-22 | Rezdiffra | $21 |
| Abbvie | Meals · 2025-10-21 | Rinvoq | $21 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-10-13 | Xifaxan | $20 |
| Abbvie | Meals · 2025-10-09 | Rinvoq | $14 |
| Madrigal Pharmaceuticals | Meals · 2025-10-07 | Rezdiffra | $32 |
| Abbvie | Meals · 2025-09-30 | Rinvoq | $23 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-09-29 | Xifaxan | $24 |
| Abbvie | Meals · 2025-09-18 | Skyrizi | $19 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-09-16 | Xifaxan | $9 |
| Ardelyx | Meals · 2025-09-11 | Ibsrela | $17 |
| Ipsen Biopharmaceuticals | Meals · 2025-09-05 | Iqirvo | $23 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-08-25 | Xifaxan | $6 |
| Micro-tech Endoscopy USA | Meals · 2025-08-20 | Riteclip | $14 |
| Abbvie | Meals · 2025-08-19 | Rinvoq | $23 |
| Abbvie | Meals · 2025-08-19 | Rinvoq | $21 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-08-11 | Xifaxan | $5 |
| Abbvie | Meals · 2025-07-31 | Rinvoq | $14 |
| Madrigal Pharmaceuticals | Meals · 2025-07-22 | Rezdiffra | $25 |
| Abbvie | Meals · 2025-07-18 | Rinvoq | $22 |
| Abbvie | Meals · 2025-07-10 | Rinvoq | $21 |
| Madrigal Pharmaceuticals | Meals · 2025-07-08 | Rezdiffra | $23 |
| Madrigal Pharmaceuticals | Meals · 2025-06-19 | Rezdiffra | $23 |
| Abbvie | Meals · 2025-05-07 | Creon | $29 |
| Ardelyx | Meals · 2025-04-17 | Ibsrela | $15 |
| Abbvie | Meals · 2025-04-16 | Creon | $0 |
| Abbvie | Meals · 2025-04-16 | Linzess | $23 |
| Abbvie | Meals · 2025-04-08 | Skyrizi | $23 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-04-07 | Xifaxan | $22 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-04-02 | Xifaxan | $24 |
| QOL Medical | Meals · 2025-03-25 | Sucraid | $22 |
| Abbvie | Meals · 2025-03-20 | Rinvoq | $23 |
| Madrigal Pharmaceuticals | Meals · 2025-03-17 | Rezdiffra | $10 |
| Abbvie | Meals · 2025-03-11 | Linzess | $17 |
| Abbvie | Meals · 2025-03-11 | Creon | $1 |
| Genzyme | Meals · 2025-03-06 | Dupixent | $30 |
| Phathom Pharmaceuticals | Meals · 2025-02-27 | Voquezna | $13 |
| Ardelyx | Meals · 2025-02-13 | Ibsrela | $18 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-02-12 | Xifaxan | $13 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-02-12 | Xifaxan | $9 |
| Abbvie | Meals · 2025-02-04 | Rinvoq | $26 |
| Celltrion USA | Meals · 2025-01-31 | Vegzelma | $14 |
| Abbvie | Meals · 2025-01-23 | Skyrizi | $25 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-01-23 | Xifaxan | $20 |
| Abbvie | Meals · 2025-01-21 | Linzess | $21 |
| Ardelyx | Meals · 2025-01-16 | Ibsrela | $23 |
| Madrigal Pharmaceuticals | Meals · 2025-01-10 | Rezdiffra | $16 |
| Phathom Pharmaceuticals | Meals · 2025-01-07 | Voquezna | $8 |
See earlier years (2024, 2023, 2022, 2021)
2024: $693
| Abbvie | Rinvoq | $435 | 23 payments
|
| Lilly USA | Omvoh | $74 | 3 payments
|
| Madrigal Pharmaceuticals | Resmetirom | $33 | 2 payments
|
| Exact Sciences | Cologuard Collection Kit | $28 | 1 payment
|
| Medtronic | Synchromedii | $27 | 1 payment
|
| Ardelyx | Ibsrela | $23 | 1 payment
|
| QOL Medical | Sucraid | $22 | 1 payment
|
| Intercept Pharmaceuticals | Ocaliva | $18 | 1 payment
|
| Phathom Pharmaceuticals | Voquezna | $17 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $16 | 1 payment
|
2023: $1,158
| AbbVie | Creon | $391 | 17 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $260 | 8 payments
|
| GlaxoSmithKline | Arexvy | $124 | 1 payment
|
| Mallinckrodt Hospital Products | Terlivaz | $119 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $51 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $48 | 2 payments
|
| Janssen Biotech | Stelara | $41 | 2 payments
|
| Celltrion USA | Zymfentra | $34 | 1 payment
|
| Genzyme | Dupixent | $31 | 1 payment
|
| Pfizer | Xeljanz | $26 | 1 payment
|
| Intercept Pharmaceuticals | Ocaliva | $19 | 1 payment
|
| Braintree Laboratories | Sutab | $14 | 1 payment
|
2022: $1,606
| Abbvie | Creon | $623 | 25 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $285 | 12 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $245 | 7 payments
|
| Intercept Pharmaceuticals | Ocaliva | $200 | 6 payments
|
| Pfizer | Xeljanz | $98 | 4 payments
|
| Janssen Biotech | Stelara | $40 | 2 payments
|
| Genzyme | Dupixent | $27 | 1 payment
|
| QOL Medical | Sucraid | $26 | 1 payment
|
| Alnylam Pharmaceuticals | Givlaari | $26 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $22 | 1 payment
|
| Daiichi Sankyo | Injectafer | $14 | 1 payment
|
2021: $1,175
| AbbVie | Linzess | $768 | 18 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $204 | 10 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $86 | 3 payments
|
| Janssen Biotech | Stelara | $51 | 3 payments
|
| Merck Sharp & Dohme | Dificid | $40 | 2 payments
|
| QOL Medical | Sucraid | $26 | 1 payment
|
Professional record
- NPI
- 1033643671
- Licence
- CA A164424California A164424: Current · expires 2027-08-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X); Hospitalist (208M00000X); Student in a training program (390200000X)
- Mailing address
- Po Box 28949, Fresno, CA, 93729
- NPI first listed
- 2017-04-19
- NPI last updated
- 2023-10-03
- NPI record certified
- 2023-10-03
This is when the NPI record was last certified, not a medical board exam.